Based on this information, we explored the effect of the demethylating enzyme ALKBH5 on the anti-PD-L1 efficacy in NSCLC through the cross-talk of tumor cells and TAMs, hoping to shed further light on the role of m6A modification in immunotherapy. Here, ALKBH5 is linked to neoplasm.